Wyss Zurich
Overview
Wyss Zurich is a joint accelerator of the University of Zurich and ETH Zurich that fosters translational research and invests in the fields of regenerative medicine, robotics, and medical devices/bionics technologies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| OxyPrem | Aug 2019 | Accelerator | Co-investor |
| Veltist | May 2025 | Accelerator | Co-investor |
| Cellerys AG | Oct 2015 | Accelerator | Lead |
| Hemotune AG | May 2017 | Grant | Co-investor |
| NovaGo Therapeutics | Jan 2015 | Grant | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Wyss Zurich based?
Wyss Zurich is headquartered in Zurich, Switzerland.
When was Wyss Zurich founded?
Wyss Zurich was founded in 2015.
How many portfolio companies does Wyss Zurich have?
Wyss Zurich has 6 portfolio companies in Caplight's dataset.
What are some companies in Wyss Zurich's portfolio?
Portfolio companies visible on Caplight include OxyPrem, Veltist, Cellerys AG, Hemotune AG, NovaGo Therapeutics.
What was Wyss Zurich's most recent investment shown here?
Wyss Zurich's most recent investment in this portfolio sample was in Veltist in 2025.
What sectors does Wyss Zurich focus on?
Wyss Zurich focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech.
What company stages does Wyss Zurich focus on?
Wyss Zurich typically invests at the Early stage.
What is Wyss Zurich's AUM?
Wyss Zurich's assets under management are estimated between $220.0M and $220.0M.